Document is current
Any future updates will be listed below
-
Authors
Ishiwa, Sho
Sato, Mai
Kamei, Koichi
Nishi, Kentaro
Kanamori, Toru
Okutsu, Mika
Ogura, Masao
Sako, Mayumi
Ito, Shuichi
Orihashi, Yasushi
Ishikura, Kenji https://orcid.org/0000-0003-2692-6437
-
Funding
Funding for this research was provided by:
Childhood-onset, rare and intractable kidney diseases in Japan, Research on rare and intractable diseases (20FC2028)
- License Information
-
More Information
Article History
Received: 13 September 2020
Accepted: 11 February 2022
First Online: 7 March 2022
Declarations
:
: K. Kamei has received grants from the Terumo Life Science Foundation and Ono Pharmaceutical Co. S. Ito has received research funding from TEIJIN PHARMA Ltd. K. Ishikura has received grants from Asahi Kasei Pharma and Novartis Pharma.
: The study was conducted in accordance with the ethical principles set out in the Declaration of Helsinki and the ethical guidelines for Medical and Health Research Involving Human Subjects created by the Ministry of Health, Labour and Welfare in Japan. The study was approved by the ethics board of the National Center for Child Health and Development (ID:2042).
: Informed consent for participating in this study was not required based on the above-mentioned guidelines.
